Akebia Therapeutics (AKBA) Goodwill (2018 - 2026)

Akebia Therapeutics (AKBA) has 9 years of Goodwill data on file, last reported at $59.0 million in Q1 2026.

• Goodwill for Q1 2026 came in at $59.0 million, changed 0.0% year-over-year; the trailing twelve-month figure through Mar 2026 was $59.0 million (changed 0.0% YoY), and the FY2025 annual result was $59.0 million, changed 0.0% from the prior year.
• Goodwill was little changed at $59.0 million in Q1 2026 per AKBA's latest filing, from $59.0 million in the prior quarter.
• Over five years, Goodwill peaked at $59.0 million in Q1 2022 and troughed at $59.0 million in Q1 2024.
• A 5-year average of $59.0 million and a median of $59.0 million in 2022 frame the typical range for Goodwill.
• The sharpest annual moves came in 2022 and 2024: Goodwill gained 7.16% in 2022, then dropped 0.07% in 2024.
• A 5-year view of Goodwill shows it stood at $59.0 million in 2022, then changed by 0.0% to $59.0 million in 2023, then retreated by 0.07% to $59.0 million in 2024, then changed by 0.0% to $59.0 million in 2025, then changed by 0.0% to $59.0 million in 2026.
• Business Quant data shows AKBA's Goodwill at $59.0 million in Q1 2026, $59.0 million in Q4 2025, and $59.0 million in Q3 2025.